For the further study, we are trying to examine that rosiglitazone, FDA approved hypoglycemic agent as PPARγ agonists, has anti-cancer activity against RCC through inhibition of JAK2 phosphorylation. This evidence concerns the gene PPARG and renal cell carcinoma.